The commentary, views and opinions expressed in this release by BMW are solely those of BMW
They began announcing that effective January 1, 2026, GLP-1 medications would only be covered for their original FDA-approved diabetes indications, not for weight management alone
This has led to clinical development of AS inhibitors Sodium/glucose cotransporter 2 (SGLT2) inhibitors are the standard of care in people with CKD with or without type 2 diabetes mellitus (T2DM) and may also mitigate potential hyperkalemia risk with AS inhibitors Vicadrostat is a highly selective AS inhibitor in clinical development for the treatment of CKD and heart failure
If that sounds familiar, our personalized GLP-1 program may be right for you
A recent retrospective cohort study found that patients with T2DM on GLP-1RAs experienced fewer asthma exacerbations compared to those on other anti-glycemic agents, having a comparative incidence rate ratio that covers the range of 1.83 to 2.98 [255]
isolated from burn patients
